Skip to content

High Flow Nasal Cannula Versus Nasal Intermittent Positive Pressure (NIPPV) in Preterm Infants

A Multicenter Randomized Controlled Trial Comparing High Flow Nasal Cannula and NIPPV in Preterm Infants

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03853161
Acronym
VAPORAM
Enrollment
130
Registered
2019-02-25
Start date
2018-01-21
Completion date
2023-07-01
Last updated
2021-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Infant

Brief summary

The aim of this study is to compare the effectiveness of Heated Humidified High Flow Nasal Cannula (HHHFNC) versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in preventing intubation when used as primary respiratory support for Respiratory Distress Syndrome (RDS) or post extubation in preterm infants

Detailed description

Patient population will include preterm infants born at 24 - 36+6 weeks of gestation who are candidates for non-invasive respiratory support post extubation or as primary respiratory support after birth. They will be will be randomized to 2 groups: Heated Humidified High Flow Nasal Cannula (HHHFNC) and Nasal Intermittent Positive Pressure Ventilation (NIPPV). This will be a prospective unblinded randomized controlled study, designed as a non-inferiority trial. Primary outcome: The primary outcome will be rate of treatment failure (need for intubation) within 7 days of starting the study treatment

Interventions

A form of non invasive ventilation used in newborns

OTHERNIPPV

A form of non invasive ventilation used in newborns

Sponsors

Carmel Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Infants born at 24-27+6 weeks of gestation and up to 28 days of life who are extubated for the first time after birth or immediately after surfactant administration via (intubation-surfactant-extubation) INSURE or (minimally invasive surfactant therapy) MIST procedures. * Infants born at 28-36+6 weeks of gestation and up to 28 days of life who are candidates for non-invasive support either as a primary modality after birth or post extubation. * Signed parental informed consent by one of the parents

Exclusion criteria

* Infants who are unlikely to survive the immediate postnatal period or who have significant congenital abnormalities * Presence of a pneumothorax prior to enrollment * Hemodynamic instability due to sepsis or hemorrhage * Inability to obtain parental consent * Shortage of suitable equipment * Infants who were intubated solely for surgery

Design outcomes

Primary

MeasureTime frameDescription
Rate of intubation within 7 days of starting the study treatmentone weekFailure of non invasive support by criteria of pH, blood carbon dioxide level, oxygen requirements or apneas

Countries

Israel

Contacts

Primary ContactAyala Gover, MD
ayalagover@gmail.com972-528-396948

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026